KRMD

Business Context and Reporting Period

Company: Repro-Med Systems, Inc. (Note: Metadata lists "KORU Medical Systems, Inc.", but the filing text identifies the registrant as Repro-Med Systems, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: August 31, 2010
Business Overview: The Company researches, develops, and markets medical devices, primarily the Freedom60 syringe infusion pump for home care and the RES-Q-VAC emergency airway suction system. The Company is classified as a smaller reporting company.

Key Financial Metrics

Margins (Six Months Ended Aug 31, 2010):

• Gross Margin: Approximately 64.6% (Calculated as Net Sales minus Cost of Goods Sold)
• Net Profit Margin: Approximately 9.2%

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 17.2% ($302,145) compared to the prior six-month period. This was driven by a 34.6% increase in Freedom60 sales ($1.66M vs $1.21M), partially offset by a 30.1% decline in RES-Q-VAC sales.
• Profitability: Net income increased 8.6% to $189,652. Despite higher sales, operating profit margins were pressured by increased Cost of Goods Sold (up 18.0%) and Selling, General, and Administrative (SG&A) expenses (up 20.9%).
• Cash Flow: Operating cash flow improved dramatically to $428,724 from $26,953 in the prior year, attributed to increased profitability, improved receivables collections, and the utilization of deferred tax assets.
• Debt Reduction: Total liabilities decreased by approximately $349,000. The Company fully repaid a $100,000 shareholder note in June 2010 and reduced other related party debt.
• Equity Changes: Preferred stock was converted to common stock (10,000 preferred shares for 952,381 common shares), and accrued preferred dividends of $68,000 were forgiven and restored to the accumulated deficit.

Guidance, Outlook, and Risks

Management Commentary: Management expects the Freedom60 market to continue growing, particularly with the introduction of a new 20% IgG drug solution. The Company believes current capital and cash flow are sufficient to meet financial needs for the next twelve months. A $150,000 government grant (Trade Adjustment Assistance Program) is being utilized to offset marketing and regulatory costs, with approximately $7,500 remaining as of August 31, 2010.

Risks and Contingencies:

• Regulatory & Reimbursement: Success depends on FDA regulations and Medicare reimbursement rates (HCPCS code E0779). Changes in reimbursement policies could adversely affect sales.
• Competition: The Company faces competition from electrically powered devices and other manual suction systems (e.g., Laerdal V-Vac, Ambu Res-Cue).
• Product Contingency: The Company is contingently liable for approximately $10,000 in rework costs for a specific customer order, which has been provisioned for.
• Market Risks: Potential introduction of new drugs (e.g., Hyaluronidase) could alter market conditions for subcutaneous infusion devices.

Investor Verification Checklist

• Revenue Concentration: Verify the extent of reliance on the Freedom60 product line versus the declining RES-Q-VAC line.
• Debt Obligations: Review the maturity schedule of the remaining $543,298 in long-term debt, noting the significant portion due after 2015.
• Related Party Transactions: Confirm the terms of the remaining $536,906 loan from a director and the lease agreement for the aircraft controlled by the President.
• Grant Utilization: Monitor the status of the $150,000 Trade Adjustment Assistance grant and its impact on future R&D and marketing expenses.
• Reimbursement Status: Verify the stability of the Medicare HCPCS code E0779 and any pending changes in reimbursement rates for mechanical infusion pumps.